Modulated gap junctional intercellular communication as a biomarker of PAH epigenetic toxicity: structure-function relationship. by Upham, B L et al.
Modulated Gap Junctional Intercellular
Communication as a Biomarker of PAH
EpigeneticToxicity: Structure-Function
Relationship
Brad L. Upham, Liliane M. Weis, and James E. Trosko
Department of Pediatrics and Human Development, Michigan State
University, East Lansing, Michigan
Cancer is a multistage multimechanism process involving gene and/or chromosomal mutations
(genotoxic events), altered gene expression at the transcriptional, translational, and post-
translational levels (epigenetic events), and altered cell survival (proliferation and apoptosis or
necrosis), resulting in an imbalance of the organism's homeostasis. Maintenance of the
organism's homeostasis depends on the intricate coordination of genetic and metabolic events
between cells via extracellular and intercellular communication mechanisms. The release of a
quiescent cell, whether normal or premalignant, from the suppressing effects of communicating
neighbors requires the downregulation of intercellular communication via gap junctions, thereby
allowing factors that control intracellular events to exceed a critical mass necessary for the cell to
either proliferate or undergo apoptosis. Therefore, determining the role an environmental pollutant
must play in the multistage carcinogenic process includes mechanisms of epigenetic toxicity such
as the effects of a compound on gap junctional intercellular communication (GJIC). A classic
example of a class of compounds in which determination of carcinogenicity focused on genotoxic
events and ignored epigenetic events is polycyclic aromatic hydrocarbons (PAHs). The study of
structure-activity relationships of PAHs has focused exclusively on the genotoxic and tumor-
initiating properties of the compound. We report on the structure-activity relationships of two- to
four-ringed PAHs on GJIC in a rat liver epithelial cell line. PAHs containing a bay or baylike region
were more potent inhibitors of GJIC than the linear PAHs that do not contain these regions. These
are some of the first studies to determine the epigenetic toxicity of PAHs at the epigenetic level.
Environ Health Perspect 106(Suppl 4):975-981 (1998). http.//ehpnetl.niehs.nih.gov/docs/
1998/Suppl4/975-981upham/abstract.html
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Introduction
ImportanceofUnderstanding dysfunction, neurologic disorders, or
theMechanisms ofToxicities hereditary diseases. What is needed is a
in RiskAssessmentafter Human mechanistic understanding ofhow the
Exposure to Chemicals chemical, by interacting with complex
The fundamental challenge to risk assessors genetic and biologic processes and develop-
exists in understanding if exposure to a mental and sex-related factors, contributes
given chemical or a mixture of chemicals to multistep processes involved in the initi-
will lead to acute lethality ofan individual ation and progression of these diseases.
or to the long-term development ofa num- Epidemiologic associations can give clues
ber of chronic diseases such as birth but cannot determine the underlying
defects, cancer, diabetes, reproductive mechanisms by which the chemical might
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have been linked to the disease end point.
Experimental animal studies, for a wide
variety of reasons, have additional limita-
tions and they also cannot provide under-
lying mechanisms by which a given
chemical might or might not lead to
human diseases. Molecular, biologic, and
cellular studies, which can provide poten-
tial mechanistic insights as to how chemi-
cals might be toxic, also suffer from
limitations ofall sorts (1).
To put chemicals in animals and check
to see ifdisease can be induced, to check
humans known to be exposed to a given
chemical for the appearance ofdisease, and
to measure DNA lesions, mutations, and
cell death in vitro will not be sufficient to
link a chemical as causing a disease via this
or that mechanism. The reason is funda-
mental; all observations, epidemiologic or
experimental bioassays, or in vitroassays are
interpreted within accepted paradigms. The
design and interpretation of the experi-
ments and results presume some under-
standing ofthe disease processes and the
techniques used to determine mechanisms.
Although the field of toxicology existed
long before Carson's Silent Spring (2) and
societies have been concerned about expo-
sures to certain chemicals since the dawn of
time, heightened concern in recent decades
has caused a rush to test chemicals already
in use and known or suspected of con-
tributing to human disease and to test
chemicals in development. Understandably,
testing protocols, guidelines for use and
exposure, and decision-making interpreta-
tions for evaluation of the results must
involve state-of-the-art information in our
understanding ofthe causes ofdisease and
the meaningofvarious test results.
Although this analysis must be limited
to one disease, namely cancer, the implica-
tions probably hold true for most, if not
all, human diseases. A major problem in
the task ofidentifying the risk of cancer
induction after exposure to a given toxicant
is understanding how cancer is produced in
a human being and how a toxicant might
contribute to that process. One can get
some idea ofthe origin ofsome ofour pre-
sent-day problems when encountering the
word carcinogen-the very word we use to
identify a toxicant known or suspected of
contributing to a cancer.
Given that our current understanding
of the carcinogenic process is of a multi-
stage multimechanism process involving
gene and/or chromosomal mutations
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(genotoxic events), altered gene expression
at the transcriptional, translational, and
post-translational levels (epigenetic events),
and altered cell survival (necrosis or apopto-
sis), it should be clear that the word car-
cinogen would imply that a toxicant could
bring about each and every mechanism in
the multistep process of carcinogenesis.
Even more succinctly, when the paradigm
"carcinogen as mutagen" was created (3), it
paralyzed the thinking of far too many
basic scientists, industrial scientists, epi-
demiologists, and policy regulators into
believing that one thing could cause cancer,
that the one thing had to be a mutagen,
and that assays to detect mutagens, when
positive, actuallydid detect mutagens (4).
Unfortunately, this whole approach was
incorrect. Carcinogenesis is not just muta-
genesis (5). Therefore, to reject, modify, or
refine our fundamental understanding of
carcinogenesis, we must create a new para-
digm. Currently, new knowledge of the
genetic bases ofvarious cancers (i.e., onco-
genes, tumor suppressor genes), the roles of
mutations, epigenetic mechanisms, and cell
death (necrosis or apoptosis) during the
carcinogenic process, the limitations ofall
bioassays and in vitro assays to detect geno-
toxicants, and the distinctive differences of
the initiation, promotion, and progression
steps ofthe carcinogenic process force us to
generate a new paradigm.
Cancer as aDiseaseofHomeostasis
The human being is a collection ofabout
100 trillion cells, consisting ofstem cells,
committed progenitor cells, and terminally
differentiated cells. These cells are all
communicating with each otherviaextracel-
lular, intracellular, and intercellular commu-
nication mechanisms (6). This integrated
complex of communicating mechanisms
regulates the major options ofcell behavior,
namely their ability to proliferate, differenti-
ate, display adaptive responses ifthey are
differentiated, and undergo apoptosis
(Figure 1). In effect, homeostasis is the end
result ofthese three major communicating
mechanisms interacting with each other.
From the onset offertilization ofthe egg by
the sperm, through growth and develop-
ment ofthe embryo and fetus, to the expres-
sion of specific genes in the neonate,
adolescent, and aging adult, health ofthe
individual depends on this delicate coordi-
nation ofthe regulation ofcell proliferation
for growth and tissue repair and regenera-
tion, for proper differentiation ofcells at
appropriate times, for adaptive responses of
cells in tissues when exposed to endogenous
or exogenous extracellular communicating
signals, and for the timely regulation of
apoptosis or programmed cell death.
Hormones, growth factors, and neuro-
transmitters produced by specific cells tra-
verse over a distance to cells having specific
receptors to bind to these extracellular sig-
nals. These cells that receive the extracellular
signals transduce the molecular information
into changes ofvarious second messages that
trigger a finite number ofdistinct signal-
transducting intracellular communicating
mechanisms. In turn, these intracellular
communicating mechanisms perform two
major functions: they modulate gap junc-
tional intercellular communication (GJIC)
between contiguous cells and epigenetically
alter the expression ofgenes or gene prod-
ucts ofthe cell. By means ofthe interlocking
sequence ofcommunicating mechanisms, a
quiescent cell that is contact inhibited can
escape the suppressing effect ofcommuni-
cating neighbors by having gap junctional
communication blocked and thereby allow-
ing the quiescent cell to accumulate the nec-
essary factors needed to exceed a critical
mass for the cell to divide. On the other
hand, extracellular communicating signals
such as hormones could modulate intracel-
lular communication within certain cells to
increase GJIC to allow differentiation (7),
adaptive responses such as contraction of
tissues (8,9) or modulation of endocrine
function, (10,11) orapoptosis (12) to occur.
Cancer cells have long been characterized
as cells with the inability to regulate their
growth [loss ofcontact inhibition (13)] and
the inability to terminally differentiate
[oncogeny as partially blocked ontogeny
(14)]. Cancer as a disease ofdifferentiation
or as a stem cell disease (15) suggests that
during the carcinogenic process these cells
lost their ability for homeostatic control.
This implies a breakdown in one of the
three communicating mechanisms.
Experimental evidence seems consistent
with the hypothesis that cancer is a break-
down in cell-cell communication (16).
Most, ifnot all, cancer cells have defective
homologous and/or heterologous GJIC
(17). Chemical tumor promoters inhibit
GJIC, whereas chemical antipromoters
enhance GJIC (18). Oncogenes downregu-
late GJIC, whereas tumor suppressor genes
upregulate GJIC (16). Antisense gap junc-
tion genes in normal cells render them can-
cerlike (19,20), whereas sense gap junction
genes transfected into cancer cells restore
their normal growth regulation (16).
Carcinogenesis as aMultistage
Multimechanism Process Involves
Both MutagenicandEpigeneticEvents
The observations that carcinogenesis
consists ofdistinct operational phases dur-
ing the evolution of a normal growth-
controlled cell to an invasive and metastatic
neoplastic growth disregulated and
Extracellularcommunication
- Translatonal regulators
-Transcriptional regulators
- Post-translational regulators
~IntracelIlular communication
orsignaltransduction
Apoptosis \
Adaptive responses
ofdifferentiated cells
Figure 1. Gapjunctions in cellular homeostasis. This diagram illustrates the integration of intercellular, intracellu-
lar, and gap junctional intercellular communication mechanisms in the homeostatic control of the four primary
functions of cells in a multicellular organism, namely, cell proliferation, cell differentiation, adaptive responses of
differentiated cells, and programmed cell death orapoptosis. Cell adhesion and cell-matrix interactions are classi-
fied as subclasses of intercellular communication.
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nonterminally differentiated cell led to the
concepts ofinitiation, promotion, and pro-
gression (21). The concepts were derived in
vivo after it was observed that subcarcino-
genic doses ofa carcinogen induced an irre-
versible event in a cell ofthe mouse skin
(initiation), which could be manifested as a
visible papilloma, after repeated chronic
exposure to a noncarcinogenic compound
such as phorbol ester (promotion) (22,23).
Further irreversible changes occurring in
these initiated cells that have been clonally
amplified by the promotion process then
leads to a malignant tumorcell (24).
Although the underlying mechanisms
for these distinct phases ofcarcinogenesis
are not yet known, it has been hypothesized
that because initiation is an irreversible
event, mutagenesis could be the mechanism
by which a normal stem cell could be irre-
versibly altered to prevent terminal differen-
tiation (21). Furthermore, when these single
initiated stem cells are exposed to agents or
conditions that stimulate them to proliferate
(promotion), the mechanism that brings
about this clonal expansion ofinitiated stem
cells that cannot terminally differentiate
would be a mitogenic or epigenetic mecha-
nism. Because the promotion phase ofcar-
cinogenesis can be interrupted, if not
reversed, when exposure to the promoting
condition or agent is stopped, it is dear that
mutagenesis cannot explain this phase of
carcinogenesis. Moreover, chemical promot-
ing agents such as phorbol esters, phenobar-
bital, saccharin, hormones, polybrominated
biphenyls, peroxisome proliferators, and
wound healing are not mutagenic. These
promoting agents and conditions all
reversiblymodulate GJIC (25).
Chemicals asCarcinogens
orCacinogens asMutagens
Chemicals are labeled carcinogens when a
population ofhumans with known expo-
sure to a chemical has a greater frequency
of tumors than those who were not
exposed or when a tumor appears in an
animal that has been given a chemical.
Until now, this carcinogen was labeled as a
mutagen for a number ofextrapolated rea-
sons, such as the cancer cell had mutations
in various genes or the chemical induced a
positive effect in an in vitro assay designed
to detect mutations. This led to the para-
digm "carcinogen as mutagen" (1).
However, mutagenicity cannot always
be equated with carcinogenicity. This is
particularly evident from the study of
Ashby and Tennant (26) in which 301
chemicals were assessed for mutagenicity
and carcinogenicity. Although this study
indicated that structurally alerting/muta-
genic agents had a high probability of
being carcinogenic (84% mutagens were
carcinogens), this correlative advantage was
offset by an unacceptable high incidence of
false-positive predictions (66% noncar-
cinogens were mutagens) (26). Also, many
nonmutagenic/nonalerting chemicals were
carcinogenic (26). This was especially true
for male rat kidney carcinogens, rodent
leukemogens and thyroid carcinogens, and
mouse liver carcinogens (26).
This unfortunately led to the negative
term nongenotoxic carcinogens. The term
does not indicate the underlying mecha-
nisms ofcarcinogenicity but refers only to
what the compound cannot do, i.e., the
compound cannot cause a permanent
genetic mutation. To the contrary, the term
epigenetic toxicity implies a mechanism of
reversibly altering the genetic phenotype of
a cell through biochemical pathways that
ultimately turn genes on and offvia intra-
cellular pathways, a process under the
homeostatic control ofneighboring cells via
intercellular communication through gap
junctions (15,16). Because intracellular
pathways often converge onto intercellular
events (15), the development of in vitro
assay systems that measure GJIC has been
successfully used to detect many epigenetic
carcinogens (27,28). Rosenkranz et al. (28)
used a structure-activity relationship model
that utilized a multicase algorithm correlat-
ing 11 different biophores of251 chemicals
with GJIC activity to show a high concor-
dance between experimental and predicted
results (74%).
PAHs as aTestofthe Hypothesis
ThatCarcinogensAreMutagens
Polycyclic aromatic hydrocarbons (PAHs)
are a group of compounds strongly sus-
pected ofbeing carcinogenic to humans
(29). The potential human carcinogenicity
ofPAHs is based on many years ofobserva-
tion in animal and in vitro bioassays, epi-
demiology, and occupational medicine (29).
Actually, the earliest association ofan envi-
ronmental agent linked to human cancer
was made by Pott (30), who reported that
prolonged contact of coal soot with skin
resulted in increased scrotal cancer in chim-
ney sweeps. The cancer-causing agent of
coal soot was attributed to PAHs contain-
ing a dibenz[a]anthracene nucleus (31).
Subsequent to this discovery, Kennaway
and Hieger (32) directly tested the carcino-
genic activity ofdibenz[a,h]anthracene,
resulting in the first demonstration of the
carcinogenicity ofa chemical with a defined
structure. Since these discoveries were made
a large-scale program to define structural
features ofchemical compounds necessary
for carcinogenic activity was begun, in
which a large number ofcompounds syn-
thesized and screened for carcinogenicity
were PAHs and heterocyclics (33). The car-
cinogenic studies ofstructure-activity rela-
tionships ofPAHs reported in the literature
focused almost exclusively on either the
complete carcinogenicity or tumor-initiat-
ing activity of PAHs (33,34). However,
reports in the literature ofthe tumor-pro-
moting properties ofPAHs are sparse. This
lack ofdata on structure-activity relation-
ships ofPAHs pertaining to tumor promo-
tion is unfortunate considering that human
risk from a carcinogen does not rest solely
on the initiating properties ofa chemical,
particularly because many suspected car-
cinogens are not genotoxic (35) and some
genotoxic agents are noncarcinogenic and
lack initiating activity (12).
For example, fluoranthene intraperi-
toneally injected into mouse neonates
showed increased lung and liver tumors in a
dose-dependent manner (35,36), but did
not show any evidence oftumor-initiating
activity in experimental animals (29) or in
in vivo genotoxicity, as assessed using the
mouse bone marrow micronucleus and rat
liver unscheduled DNA synthesis assays
(37). The tumor-promoting activityoffluo-
ranthene has not been determined; however,
fluoranthene downregulates GJIC in a rat
liver epithelial cell line (38), which suggests
that fluoranthene may be a tumor promoter
because ofits epigenetic properties.
Understanding the molecular basis of
the carcinogenicity of PAHs must include
a study of nongenotoxic series of epige-
netic events such as those that affect GJIC,
for reasons outlined in our discussion of
GJIC biology.
Some structure-activity relationships of
PAHs and GJIC have been reported by
Upham et al. (39), who showed that
monomethyl isomers of anthracene that
possessed a baylike region (Figure 2) were
more inhibitory than the parent compound
or the monomethyl isomer containing no
baylike region.
A PAH containing a bay region, such as
phenanthrene (Figure 2), was also more
inhibitory than anthracene (38). To fur-
ther explore the possibility that PAHs con-
taining bay or baylike regions are more
inhibitory to GJIC, we compared the
effects of naphthalene, 1-methylnaphtha-
lene, 2-methylnaphthalene, anthracene,
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1-methylanthracene, 2-methylanthracene,
9-methylanthracene, phenanthrene, fluo-
rene, 1-methylfluorene, and fluoranthene
on GJIC in rat liver epithelial cells. The
basic structures are shown in Figure 2.
Results and Discussion
Methylnaphthalene, which contains a bay-
like region, inhibited GJIC at a lower dose
than the linear naphthalenes (Table 1). The
8 1
Naphthalene Ba8 k9 CH3
6 3
5 10 4
1-Methylanthracene
8 9 1
7 2
5 4
Fluorene Bay
Phenanthrene
Fluoranthene
Figure 2. The basic structures of polycyclic aromatic
hydrocarbons. Examples of bay and baylike regions are
shown and numbers are given to locate the position of
the methyl group.
increased inhibitory effect ofPAHs contain-
ing bay or baylike regions was even more
pronounced with the three-ring PAHs
(Table 2). The linear PAHs did not inhibit
GJIC even at the highest doses tested, but
the PAHs containing either a bay or baylike
region inhibited GJIC at a dose of 50 pM
(Table 2). There was very little difference in
the potency of PAHs containing multiple
baylike regions (i.e., 9-methylanthracene
Table 2. Effect of the three-benzene-ringed polycyclic
aromatic hydrocarbons.
Concentration,
Structural pM at 90%
PAH determinant inhibitiona
Anthracene Linear >350b
2-Methylanthracene Linear >350b
1-Methylanthracene Baylike 50
9-Methylanthracene Baylike 50
9,10-Dimethylanthracene Baylike 50
Phenanthrene Bay 50
aGJIC was measured by the scrape-load/dye transfer
technique according to the method of Upham et al. (64)
using WB rat liver epithelial cells. The incubation time
of the indicated chemical with the cells was 10 min.
bAt the maximum soluble concentration of 350 pM, no
inhibition was observed.
Table 3. Effect of the fluorene-type polycylic aromatic
hydrocarbons.
Concentration,
Structural pM at 90%
determinant inhibitiona PAH
Fluorene Linear 75
1-Methylfluorene Baylike 30
Fluoranthene Bay 30
'GJIC was measured by the scrape-load/dye transfer
technique according tothe method of Upham et al. (64)
using WB rat liver epithelial cells. The incubation time
ofthe indicated chemical with the cells was 10 min.
and 9,10-dimethylanthracene) versus a PAH
containing a single baylike region (1-
methylanthracene) (Table2).
PAHs containing bay regions such as
phenanthrene and fluoranthene were
equally as inhibitory to their counterparts
containing baylike regions, such as
1-methylanthracene and 1-methylfluorene
(Tables 2 and 3). However, fluorene,
which contains no bay or baylike region,
did inhibit GJIC but at a higher dose than
fluoranthene (Table 3). Apparently the
pentyl ring, in addition to bay regions, also
increased the toxic effect of a PAH
on GJIC.
Inhibition ofGJIC by all ofthe PAHs
tested was also a reversible process.
Complete recovery occurred within 2 hr
and 50% recovery occurred within 1 hr
after replacing the PAH-containing
medium with that of fresh growth
medium. These results are consistent with
the reversible nature of tumor promotion
in vivo (16). Inhibition occurred in a short
time period (< 5 min) for all of the PAHs
(Table 4), indicating that the gap junction
proteins are being modified at the post-
translational level. The more water-soluble
GJIC-inhibiting PAHs, which have lower
log octanol/water partition coefficients (log
Kow), downregulated GJIC in a shorter
time period than the less water-soluble
PAHs (Table 4). This relationship oflog
Kow versus inhibition of a PAH was linear
with an r2 of0.69 and could indicate that
the cell receptor for the PAHs is more
accessible in an aqueous environment.
The tumor-promoting activity of the
PAHs used in our study has not been
determined. However, the cocarcinogenic
effect ofbenz[a]anthracene, phenanthrene,
fluoranthene, and 3-methylcholanthrene,
all ofwhich possess bay or baylike regions,
Table 1. Effect of naphthalene-type polycyclic aro-
matic hydrocarbons on gap junctional intercellular
communication.
Concentration,
Structural pM at90%
PAH determinant inhibitiona
Naphthalene Linear >350b
2-Methyinaphthalene Linear 350
1-Methyinaphthalene Baylike 225
'GJIC was measured by the scrape-load/dye transfer
technique according to the method of Upham et al. (64)
using WB rat liver epithelial cells obtained from J.W.
Grisham and M.S. Tsao (University of North Carolina,
Chapel Hill, NC). The incubation time of the indicated
chemical with the cells was 4 min. bAt the maximum
soluble concentration of 350 pM, naphthalene inhib-
ited GJIC approximately 50%.
Table 4. Linear relationship of the water/octanol partition coefficient versus the time required for a polycylic aro-
matic hydrocarbon to inhibitgapjunctional intercellular communication at 0.5fraction ofthe control.
Time of inhibition,
PAH log K0w8 minb
1-Methyinaphthalene, 200pM 3.87 0.45
2-Methyinaphthalene, 320 pM 3.86 0.89
Fluorene, 125 pM 4.18 1.59
1-Methylfluorene, 80 pM 4.50 1.74
Phenanthrene, 50 pM 4.57 2.81
9-Methylanthracene, 50 pM 5.07 2.02
1-Methylanthracene, 50 pM 5.2 2.41
Fluoranthene, 80 pM 5.22 2.64
9,10-Dimethylanthracene, 50 pM 5.25 2.29
'The log K0wvalues were obtained from Mackay et al. (65). bValues were obtained by fitting a sigmoidal curve to
data plotted as a function of GJIC expressed as a fraction of the control vs time using least-squares curve-fitting
procedures, and the numerical parameters obtained from these curves were used to calculate the time in which
inhibition occurred at a value 0.5 ofthe fraction ofthe control.
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increased the initiating and promoting
activity of benzo[a]pyrene (B[a]P)
(40-44). These cocarcinogenic PAHs are
not complete carcinogens (33) in which
phenanthrene and fluoranthene lack
tumor-initiating activity (37,41,45,46).
The concept ofbay or baylike regions pos-
sessing tumor-promoting activity certainly
warrants further investigation.
The methylated PAHs are more potent
carcinogens than their unmethylated par-
ent structure (45-53). Bioalkylation of
PAHs converts noncarcinogenic PAHs to
carcinogenic PAHs (54,55) and the methyl
substitution occurs in vivo at the meso-
anthracenic positions (53-56), which
creates a baylike region. To be complete
carcinogens, the methylated PAHs must
undergo metabolic activation into a strong
electrophile capable ofreacting with DNA.
Microsomal enzymes hydroxylate methyl
groups (56-58), and hepatic sulfotrans-
ferases catalyze the formation of sulfate
esters with the hydroxymethyl groups
(58-60). Unfortunately, experiments were
not conducted to determine whether
enhanced carcinogenicity was a conse-
quence ofincreased tumor initiation activ-
ity by the more electrophilic metabolites or
due to greater promotional activity, which
could be a consequence of the less elec-
trophilic methyl PAHs as well as the
hydroxy methylsulfonates. Another classic
example ofa methylated PAH being more
carcinogenic than the unmethylated coun-
terpart is chrysene. However, the higher
carcinogenic potential of5-methylchrysene
and its metabolites could not be related to
its mutagenic potential (61). Thus, the for-
mation of more electrophilic metabolites
and stronger mutagens is not always
essential in determining the carcinogenic
potential of a PAH but can still exert a
tumorigenic effect at the epigenetic stage
of cancer by promoting preexisting
spontaneously initiated cells.
In fact, carcinogenic PAHs are also effec-
tive modulators ofsignal transduction path-
ways involved in cell proliferative processes.
B[a]P and 7,12-dimethylbenz[a]anthracene
increase intracellular Ca2+ and cell prolifera-
tion in primary human mammary epithelial
cells (62). Another example is the induction
ofproliferation ofvascular smooth cells by
B[a]P that did not involve mutational acti-
vation ofc-Ha-, c-Ki-, or N-ras genes (63).
Clearly, a better understanding ofthe cell
proliferative roles ofPAHs in tumor promo-
tion will need further research in the effects
ofPAHs on mitogenic signal transduction
pathways and the release ofa transformed
cell from normal homeostatic control mech-
anisms maintained by GJIC. Determining
structure-activity relationships relative to
intra- and intercellular communication
should help in predicting the carcinogenic
potential ofthe many different PAHs found
in ourenvironment.
Useful information can be obtained
from in vitro experiments even though in
vitro results are difficult to extrapolate to in
vivo situations pertaining to the carcino-
genic risk ofa chemical. In vitro assays are
usually better suited for studying struc-
ture-activity relationships at a more mech-
anistic level, which can increase our ability
to predict the potency oftumor promoters
based on chemical structure. Also, in vitro
studies can ultimately reduce the extent of
whole-animal testing. For example, our
results showed that the effects ofdose, time
response, and time of recovery of the
three-ring and fluorene-type PAHs on
GJIC were similar (Tables 1-4). These
results suggest a similar mechanism of
action. Therefore, randomly selecting one
or two ofthese chemicals rather than test-
ing all of them could minimize in vivo
experiments. Minimizing in vivo experi-
ments is a particularly important motiva-
tion factor in reducing the expense and use
oflive animals when assessing the risk of
chemicals before and after environmental
remediation. To test every subtle change in
existing environmental remediation strate-
gies using in vivo assays would certainly be
prohibitively costly and inhumane, and to
limit in vitro assays to the measurement of
genotoxicity would exclude the accurate
assessment of risks to human health con-
sidering that many chemicals, including
many carcinogens, are epigenetically toxic
(16,17). Furthermore, monitoring the lev-
els of known toxicants using analytical
chemical techniques is not an acceptable
alternative to eliminating in vivo experi-
ments because simply removing the parent
compound does not always ensure a safe
environment: Toxic by-products could
result from the chemical or biologic trans-
formation ofthe parent compound (64).
An example ofsuch a situation was demon-
strated by Upham et al. (38,64), in which
selected PAHs were oxidatively removed
using ozone but the resulting mixture
became more epigenetically toxic than the
parent compound.
In conclusion, the evaluation of
epigenetic toxicity using in vitro assays
should provide invaluable information in
assessing the toxic risk of pollutants on
human health before and after environ-
mental remediation.
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